Davis Todd C's Form 4 filing
Ligand Pharmaceuticals Inc (LGND) · filed May 13, 2025
- Accession no.
- 0002001011-25-000029
- Filed
- May 13, 2025
- Trade date
- May 9, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $1.00M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Davis Todd CCIK 0001392029 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 9, 2025 | Common Stock | PPurchaseAcquired | +1,680 | $104.57 | +$175,677.6 | 153,404 | Direct | |
| May 9, 2025 | Common Stock | PPurchaseAcquired | +2,307 | $104.53F1 | +$241,150.71 | 155,711 | Direct | |
| May 9, 2025 | Common Stock | PPurchaseAcquired | +5,523 | $105.67F2 | +$583,615.41 | 161,234 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $104.1300 to $105.1000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $105.1300 to $106.0000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.